PR86129

HONG KONG, Oct. 16, 2020 /PRNewswire=KYODO JBN/ --

Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and

Insilico have entered into a research collaboration to identify novel

therapeutics against aging. Insilico Medicine will utilize both the target

discovery and generative chemistry parts of its Pharma.AI (https://c212.net/c/link/?t=0&l=en&o=2949950-1&h=526957075&u=http%3A%2F%2Fwww.pharma.ai%2F&a=Pharma.AI )

platform in this collaboration. It will use its proprietary Pandomics

Discovery Platform (https://c212.net/c/link/?t=0&l=en&o=2949950-1&h=1887706065&u=https%3A%2F%2Fpandomics.com%2Fcovidomics%2F&a=Pandomics+Discovery+Platform ) to identify novel targets for senolytic drugs and Chemistry42 platform

(https://c212.net/c/link/?t=0&l=en&o=2949950-1&h=4114055493&u=https%3A%2F%2Finsilico.com%2Fchemistry42%2F&a=Chemistry42+platform )

for a molecular generation. This collaboration brings together Insilico's

state-of-art artificial intelligence (AI) technologies in drug discovery with

Taisho's expertise in drug development, aimed to extend the human healthspan.

Photo - https://mma.prnewswire.com/media/1312850/Insilico_Taisho.jpg    

"We're delighted to collaborate with Taisho pharmaceutical, a well-recognized

leader in the pharmaceutical industry and healthcare sector. It is believed

that aging is a universal phenomenon that we cannot stop. However, emerging

scientific evidence has shown that one may be able to reverse some of the

age-associated processes. Through this collaboration, we will adopt our

AI-powered drug discovery suites together with Taisho's validation platform to

explore the new space of anti-aging solutions," said Jimmy Yen-Chu Lin, PhD,

CEO of Insilico Medicine Taiwan, a fully-owned subsidiary of Insilico Medicine

Under the terms of the agreement, Insilico Medicine will receive an upfront

payment and milestone payments upon achievement of specified goals. Insilico

Medicine will be responsible for early research phase target identification and

molecular generation and Taisho will work collaboratively with Insilico in

validating the results in various in vitro and in vivo assays. Taisho has the

exclusive option to acquire Insilico's co-ownership of the successfully

developed programs under agreed payment.

"It is our great honor to be collaborating with the scientists of Taisho

Pharmaceutical, one of the top 100 pharmaceutical companies in the world

operating since 1912. The high level of the scientists we are interfacing, and

our previous successes in the application of the Pharma.AI platform for

discovery of novel targets and molecules in fibrosis, and previous experience

in senolytic drug discovery give us confidence that this collaboration will be

successful," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

About Taisho Pharmaceutical Co., Ltd.

https://www.taisho.co.jp/global/ 

Media Contact

For further information, images or interviews, please contact:

ai@insilico.com

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement

learning (RL), and other modern machine learning techniques for the generation

of new molecular structures with the specified parameters, generation of

synthetic biological data, target identification, and prediction of clinical

trials outcomes. Recently, Insilico Medicine secured $37 million in series B

funding. Since its inception, Insilico Medicine raised over $52 million,

published over 100 peer-reviewed papers, applied for over 25 patents, and

received multiple industry awards. Website http://insilico.com/

SOURCE: Insilico Medicine Hong Kong Limited